Two drug combos for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a two-drug combination (trifluridine/tipiracil plus regorafenib) against a standard pair (trifluridine/tipiracil plus bevacizumab) for people with advanced colorectal cancer that has stopped responding to prior treatments. It aims to find which combination works better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced colon or rectal cancer that has spread and hasn't responded to earlier treatments.
- You have already tried at least a fluoropyrimidine, irinotecan, and oxaliplatin, plus a drug that targets blood vessels (anti-VEGF).
- You can swallow tablets and are in good enough health to be active (ECOG 0-1).
- Your blood counts, liver, and kidney function are within certain limits.
- You have not taken trifluridine/tipiracil or a TKI before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (regorafenib and sintilimab) plus electroacupuncture for people with advanced colorectal cancer that hasn't responded to standard treatments. The goal is to see if this triple therapy can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two drugs (cadonilimab and an anti-angiogenic agent) for advanced colorectal cancer that has a specific genetic feature (dMMR or MSI-H). It aims to find a new treatment option that might work better than current therapies.
This study tests a new combination of short-course radiation followed by two targeted drugs (fruquintinib and sintilimab) compared to standard therapy (bevacizumab and capecitabine) for people with advanced colorectal cancer who cannot tolerate strong chemotherapy. It aims to see if this gentler approach works as well or better.
This Phase 2 study tests whether adding TAS-102 to regorafenib works better than regorafenib by itself for metastatic colorectal cancer after at least one prior treatment has stopped working. It aims to improve how long the cancer can be controlled for patients in later treatment lines.
This trial tests a combination of two drugs, regorafenib and 5-FU with leucovorin, for people with colorectal cancer that has spread and has not responded to at least two previous treatments. The goal is to see if this new mix can help shrink or control the cancer.
This trial compares two combination treatments for people with advanced colorectal cancer that has stopped responding to standard therapies. You would receive either trifluridine/tipiracil plus fruquintinib or trifluridine/tipiracil plus bevacizumab, to see which combination works better.
Hear when a new Colorectal Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.